Shares of Coloplast (CSE:COLOb) climbed 3.5% as the medical device company reported first-quarter revenue in line with ...

Coloplast AS (CLPBF) reports robust 8% organic growth and a 27% EBIT margin, while addressing challenges in Interventional ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Q1 2025 Management View CEO Kristian Villumsen highlighted 8% organic growth and a reported EBIT margin of 27% for Q1 2025, which aligned with expectations. He emphasized the divestment of the Skin ...

Kepler Capital analyst Maja Pataki maintained a Hold rating on Coloplast A/S (0QBO – Research Report) on February 4 and set a price target of ...

December 2024 Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported ...

Coloplast has multiple credible long-term growth drivers, including share growth in the U.S., overall share growth in wound care, and new product introductions. Coloplast has recently been missing ...

Sanford C. Bernstein upgraded shares of Coloplast A/S (OTCMKTS:CLPBY – Free Report) from a hold rating to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports. Several other ...

Ladies and gentlemen, welcome to the Coloplast A/S Q1 2024-'25 Earnings Release Conference Call. I'm Valentina, the Chorus Call operator. [Operator Instructions] The conference must not be ...

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market ...

Bernstein analysts have revised their ratings for key players in the European medical devices and services sector, upgrading ...